Sign In
Buy ZEAL
$17.59
+0 (+0%)
At Close: Jan 27, 2023
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
11:01am, Thursday, 30'th Apr 2026
Press Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
01:01pm, Wednesday, 29'th Apr 2026
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management Phase 3 trials for chronic weight management
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful met
Company announcement – No. 9 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenha
Company announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenha
Company announcement - No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April
Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, Apr
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
10:00am, Tuesday, 14'th Apr 2026
Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmaceuticals and Shire Copenh
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
04:00pm, Tuesday, 31'st Mar 2026
Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” o
Resolutions from Zealand Pharma's Annual General Meeting 2026
11:57am, Thursday, 26'th Mar 2026
Company announcement – No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the “Company”) (Na
Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambr
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
05:00pm, Thursday, 19'th Mar 2026
Company announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S (“Zealand
Zealand Pharma to participate in upcoming investor conferences in March 2026
12:01pm, Monday, 09'th Mar 2026
Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living
Zealand Pharma convenes its Annual General Meeting 2026
08:00am, Thursday, 19'th Feb 2026
Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nas
